TriangleNCT03601897 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 90% Confidence Interval
- Time frame
- First Dose of Study Drug to Death due to Any Cause (Up to 2.82 years)
What was measured
Time from first dose of study drug to date of death due to any cause. Participants who were still alive or who were lost to follow-up will be censored at the date of last contact.
Analysis population: mITT participants that were evaluable for this outcome measure.
Groups in this outcome
Part 1 Arm 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
Dose escalation of rebastinib 50 mg BID PO in combination with paclitaxel administered by IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
Part 1 Arm 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2
Dose escalation of rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
Part 2 Cohort 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
Dose expansion in TNBC. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
Part 2 Cohort 1 Rebastinib 100 mg + Paclitaxel 80 mg/m^2
Dose expansion in TNBC. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
Part 2 Cohort 2 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
Dose expansion in inflammatory breast cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
Part 2 Cohort 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2
Dose expansion in inflammatory breast cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
Part 2 Cohort 3 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
Dose expansion in ovarian cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
Part 2 Cohort 3 Rebastinib 100 mg + Paclitaxel 80 mg/m^2
Dose expansion in ovarian cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
Part 2 Cohort 4 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
Dose expansion in endometrial cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
Part 2 Cohort 4 Rebastinib 100 mg + Paclitaxel 80 mg/m^2
Dose expansion in endometrial cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
Part 2 Cohort 5 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
Dose expansion in gynecological carcinosarcoma (GCS). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
| Group | Source count |
|---|---|
| Part 1 Arm 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | 18 |
| Part 1 Arm 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2 | 14 |
| Part 2 Cohort 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | 10 |
| Part 2 Cohort 1 Rebastinib 100 mg + Paclitaxel 80 mg/m^2 | 6 |
| Part 2 Cohort 2 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | 13 |
| Part 2 Cohort 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2 | 4 |
| Part 2 Cohort 3 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | 26 |
| Part 2 Cohort 3 Rebastinib 100 mg + Paclitaxel 80 mg/m^2 | 9 |
| Part 2 Cohort 4 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | 20 |
| Part 2 Cohort 4 Rebastinib 100 mg + Paclitaxel 80 mg/m^2 | 14 |
| Part 2 Cohort 5 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | 19 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1 Arm 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | 5.2 | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
| Part 1 Arm 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | NA | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
| Part 2 Cohort 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | NA | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
| Part 2 Cohort 1 Rebastinib 100 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | 5.4 | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
| Part 2 Cohort 2 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | NA | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
| Part 2 Cohort 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | NA | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
| Part 2 Cohort 3 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | NA | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
| Part 2 Cohort 3 Rebastinib 100 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | 6.3 | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
| Part 2 Cohort 4 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | NA | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
| Part 2 Cohort 4 Rebastinib 100 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | NA | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
| Part 2 Cohort 5 Rebastinib 50 mg + Paclitaxel 80 mg/m^2 | NA | Not reported | 5.1 | NA | OS median and 90% CI were not estimable due to insufficient number of events. |
Complete source fields
- classes
- categories
- measurements
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG000
- lower Limit
- 5.2
- upper Limit
- NA
- value
- NA
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG001
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG002
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG003
- lower Limit
- 5.4
- upper Limit
- NA
- value
- NA
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG004
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG005
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG006
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG007
- lower Limit
- 6.3
- upper Limit
- NA
- value
- NA
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG008
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG009
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- OS median and 90% CI were not estimable due to insufficient number of events.
- group Id
- OG010
- lower Limit
- 5.1
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 18
- group Id
- OG001
- value
- 14
- group Id
- OG002
- value
- 10
- group Id
- OG003
- value
- 6
- group Id
- OG004
- value
- 13
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 26
- group Id
- OG007
- value
- 9
- group Id
- OG008
- value
- 20
- group Id
- OG009
- value
- 14
- group Id
- OG010
- value
- 19
- units
- Participants
- description
- Time from first dose of study drug to date of death due to any cause. Participants who were still alive or who were lost to follow-up will be censored at the date of last contact.
- dispersion Type
- 90% Confidence Interval
- groups
- description
- Dose escalation of rebastinib 50 mg BID PO in combination with paclitaxel administered by IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG000
- title
- Part 1 Arm 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
- description
- Dose escalation of rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG001
- title
- Part 1 Arm 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2
- description
- Dose expansion in TNBC. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG002
- title
- Part 2 Cohort 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
- description
- Dose expansion in TNBC. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG003
- title
- Part 2 Cohort 1 Rebastinib 100 mg + Paclitaxel 80 mg/m^2
- description
- Dose expansion in inflammatory breast cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG004
- title
- Part 2 Cohort 2 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
- description
- Dose expansion in inflammatory breast cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG005
- title
- Part 2 Cohort 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2
- description
- Dose expansion in ovarian cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG006
- title
- Part 2 Cohort 3 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
- description
- Dose expansion in ovarian cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG007
- title
- Part 2 Cohort 3 Rebastinib 100 mg + Paclitaxel 80 mg/m^2
- description
- Dose expansion in endometrial cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG008
- title
- Part 2 Cohort 4 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
- description
- Dose expansion in endometrial cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG009
- title
- Part 2 Cohort 4 Rebastinib 100 mg + Paclitaxel 80 mg/m^2
- description
- Dose expansion in gynecological carcinosarcoma (GCS). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
- id
- OG010
- title
- Part 2 Cohort 5 Rebastinib 50 mg + Paclitaxel 80 mg/m^2
- param Type
- MEDIAN
- population Description
- mITT participants that were evaluable for this outcome measure.
- reporting Status
- POSTED
- time Frame
- First Dose of Study Drug to Death due to Any Cause (Up to 2.82 years)
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice